Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACT100 in Healthy Participants
NCT07408908Phase 1Not yet recruiting
- Sponsor
- Xiamen Tebao Biological Engineering Co., Ltd.
- Start
- Mar 2026
- Primary completion
- Mar 2027
- Modality
- Monoclonal Antibodies
01
Overview
Phase 1, randomised, double-blind trial of ACT100 in systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE), sponsored by Xiamen Tebao Biological Engineering Co., Ltd. Primary endpoints: Adverse Event, Serious Adverse Event and 2 more. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
ACT100
03
Conditions
systemic lupus erythematosus (SLE)cutaneous lupus erythematosus (CLE)
Beyond the preview
Go deeper on NCT07408908.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07408908.